Blood Res 2022; 57(1): 69-74
Myeloproliferative neoplasm with basophilia and abnormality of platelet-derived growth factor receptor a translocation: a case report
Jong Gwon Choi1,2, Do Yeun Cho1
1Department of Oncology-Hematology, Konyang University Hospital, 2Department of Internal Medicine, Myunggok Medical Research Center, Deajeon, Korea
Correspondence to: Jong Gwon Choi
Department of Internal Medicine, Myunggok Medical Research Center, 158 Gwanjeodong-ro, Daejeon 35365, Korea
Received: July 31, 2021; Revised: September 24, 2021; Accepted: December 24, 2021; Published online: March 31, 2022.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

TO THE EDITOR: Translocation of platelet-derived growth factor receptor A (PDGRFA)-protein kinase cGMP-dependent 2 (PRKG2) is uncommon in myeloproliferative neoplasms. We report a rare case of a patient presenting Philadelphia-negative myeloproliferative neoplasms with peripheral basophilia. The patient was a 38-year-old man with splenomegaly and leukocytosis. Peripheral blood examination revealed normocytic and normochromic red blood cells, no polychromasia, an increased WBC count with no toxic granulation or vacuolations, some blasts, basophilia, and an increased platelet count. Laboratory tests revealed a white blood cell count of 30,000/mL, hemoglobin level of 11.6 g/dL, and platelet count of 789,000/mL. WBCs comprised 30% segmented neutrophils, 13% lymphocytes, 1% monocytes, 4% eosinophils, and 47% basophils. Bone marrow biopsy showed estimated cellularity of ∼100%, and the numbers of immature cells and basophils were increased. Multifocal fibrosis was also observed. The PDGRFA-PRKG2 fusion gene was observed through next-generation gene sequencing, and targeted imatinib therapy was selected using an artificial intelligence matching algorithm. Immediately after treatment, the patient’s symptoms improved immediately, and his WBC count was normalized. Our results identify the first case of PDGRFA-PRKG2 fusion in an unclassified myeloproliferative neoplasm. This case also shows that the use of imatinib is very effective in treating specific myeloproliferative neoplasms with the PDGRFA-PRKG2 translocation.


Patients, occasionally meet the general criteria for classifying their condition as a myeloproliferative neoplasm (MPN) but may not meet all criteria for a particular disease or may exhibit more than one category of diagnostic characteristics. These patients can be diagnosed as MPN unclassifiable (MPN-u). Symptoms are similar to typical MPNs and usually include hepatosplenomegaly and increased numbers of white blood cells (WBCs) and platelets. A bone marrow biopsy reveals megakaryocyte proliferation and hypercellularity in granulocytes or erythrocytes. As the disease progresses, the bone marrow becomes more fibrotic. However, in the current patient, BCR-ABL, CARL, MPL, and JAK2 gene mutations, commonly observed in MPNs, were all negative. The patient was treated with hydroxyurea and ruxolitinib due to leukocytosis, hyperbasophilia, and splenomegaly, but there was no improvement. Myeloproliferative diseases often have mutations or rearrangements of protein tyrosine kinase genes such as JAK2, FGFR1, platelet-derived growth factor receptor A (PDGFRA), and PDGFRB [1, 2]. A variety of chromosomal translocations involving PDGFRA have been identified revealing that it can fuse with many different partner genes. PDGFRA and PDGFRB are transmembrane glycoproteins in the type III receptor tyrosine kinase family. This family also contains KIT, FLT3, and c-FMS. Platelet-derived growth factors (PDGFs) include a group of mitogens comprising five dimeric forms derived from pairs of A, B, C, and D peptide chains (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD). PDGFRA binds to the A, B, and C chains. PDGFRB binds to B and D chains. PDGFRA and PDGFRB are transmembrane glycoproteins belonging to the type III receptor tyrosine kinase family [3]. In 2003, the FIP1L1-PDGFRA mutation was described in relation to the MPN phenotype characterized by eosinophilia and mastocytosis [4]. The FIP1L1-PDGFRA fusion gene was highly sensitive to low-dose imatinib; complete molecular remission could be achieved with 100 mg/day and a 300 mg/week maintenance dose [5]. To date, four PDGFRA fusion genes have been identified including FIP1L1-PDGFRA, BCR-PDGFRA, ETV6-PDGFRA, and CDK5RAP2-DGFRA by the nested real-time polymerase chain reaction [6-8]. However, these mutations have been reported to exhibit clinical patterns of hyperbasophilia. In this study, we report a case of MPN-u associated with basophilia and the protein kinase cGMP-dependent 2 (PRKG2)-PDGFRA translocation, which was improved following imatinib treatment.


A 38-year-old man presented to the Konyang University Hospital (Deajeon, South Korea) on March 10, 2017, with abdominal pain that started 2 months before, and thrombocytosis was identified at a local clinic. At the time of admission, the patient had a blood pressure of 130/90 mmHg, heart rate of 78 beats per minute, respiratory rate of 20 breaths per minute, and body temperature of 37°C. There was no significant previous medical history of hypertension, diabetes mellitus, or tuberculosis. On physical examination, we observed organomegaly in the right upper quadrant of the abdomen. However, there was no enlargement of the cervical, axillary, or inguinal lymph nodes. Other examinations were unremarkable. Laboratory tests showed WBCs at 30,300/mL, hemoglobin at 9.4 g/dL, and platelets at 836,000/mL. White blood cells were composed of 24% segmented neutrophils, 17% lymphocytes, 1% monocytes, 3% eosinophils, and 51% basophils. The reticulocyte count was within the normal range. Leukemic blasts were observed in 2% of the cells. Coagulation tests revealed a prothrombin time of 16.4 seconds and an activated partial thromboplastin time of 35.5 seconds. He had a fibrinogen level of 3.13 g/L, D-dimer level of 2.1 mg/mL, and antithrombin activity of 72% (not suggestive of disseminated intravascular coagulation). Peripheral blood showed normocytic and normochromic red blood cells, no polychromasia, a normal WBC count with no toxic granulation or vacuolations, and an increased platelet count. The serum lactate dehydrogenase level was 832 U/L (normal range, 120–240 U/I). The total bilirubin level was 1.04 mg/dL (normal range, 0–0.4 mg/dL). Results for other blood factors, including creatinine and bicarbonate, and liver function tests, were unremarkable. Computed tomography revealed hepatosplenomegaly (16 cm) without an intrasplenic mass. Bone marrow aspiration revealed no particles or peripheral dilution, and immature cells were observed occasionally (Fig. 1). Bone marrow biopsy showed estimated cellularity of approximately 100%, which was hypercellular for the patient’s age. In cellular areas, trilineage hematopoiesis was observed, along with increased numbers of basophils and immature cells. In addition, there were increased numbers of dysplastic megakaryocytes, and diffuse fibrosis was observed in multiple focal areas throughout the bone marrow space (Fig. 2). The JAK2 V617F, and BCR/ABL1 mutations were not detected with the real-time polymerase chain reaction. In chromosome analysis, of the 20 metaphase cells that could be observed, all cells were subjected to 46, XY normal karyotype. The initial formal pathologic diagnosis was deferred, so the patients received hydroxyurea 200 mg twice daily. However, leukocytosis continued, and the basophilia did not improve. The WBC count eventually increased to 88,000/mL, and a bone marrow biopsy was performed again. The second formal pathologic diagnosis was MPN with myelofibrosis. The patient additionally received 20 mg ruxolitinib phosphate twice daily. Although the WBC count decreased to 32,000/mL, basophilia persisted. Various symptoms, such as splenomegaly, basophilia, and leukocytosis continued after more than a year of treatment. Finally, the patient was able to undergo next-generation gene sequencing (NGS). Targeted sequencing was performed for translocation detection using the HemaSCAN panel (Level.1), which includes the whole exomes of 427 cancer-associated genes, and the intronic regions of 23 genes. The sequencing library was constructed with DNA extracted from bone marrow aspiration blood, and sequencing was performed on a NextSeq550Dx with a 75 bp read (Illumina). Post-sequencing data were analyzed using a bioinformatics pipeline (HemaSCAN version 1.0) from Labgenomics. This test identified a driver mutation, that is, the PRKG2-PDGFRA translocation (Table 1). Based on artificial intelligence matching algorithm (HemaSCAN version 1.0), imatinib treatment was immediately initiated. Within a month of treatment, the WBC level was within the normal range, and the basophil level was reduced to 1%. The patient was treated with imatinib for more than a year, and the PDGRFA-PRKG2 translocation disappeared in a repeated NGS test (Table 2). All of the patient’s blood tests results returned to normal and splenomegaly improved.

Table 1

Results of next generation gene sequencing before imatinib treatment. PRKG2-PDGFRA translocation with 33.6% variant allele frequency and breakpoints at exon 10 of PRKG2 and exon 12 of PDGFRA.

A. Annotated variants
B. Known variants
GeneRefseqIDExonDNAchangeAAchangeFuncChrPosRead depthVAFCOSMICdbSNP
MKI67NM_002417exon14c.9670C>Tp.R3224Wnonsynonmous SNVchr10:129899557174642.55%COSM916078rs754802357
MCU2NM_002457exon30c.5356A>Cp.K1786Qnonsynonmous SNVchr11:10935376978.03%COSM4145288rs80200693
LRRK2NM_198578exon11c.1256C>Tp.A419Vnonsynonmous SNVchr12:40646786102044.41%COSM147473rs34594498
BCL7ANM_020993exon4c.359A>Cp.N120Tnonsynonmous SNVchr12:12248187972446.55%COSM5880386rs34821485
WDR90NM_145294exon16c.1804C>Tp.R602Wnonsynonmous SNVchr16:70565875844.2%COSM3273238rs201699835
PALB2NM_024675exon4c.925A>Gp.I309Vnonsynonmous SNVchr16:23646942171045.5%COSM3957351rs3809683
ZNF24NM_006965exon3c.427C>Tp.L143Fnonsynonmous SNVchr18:32919934105443.93%COSM5854150rs148053646
GeneRefseqIDExonDNAchangeAAchangeFuncChrPosRead depthVAFCOSMICdbSNP
MSH6NM_000179exon10c.4065_4066insTTGAp.T1355fsframeshift insertionchr2:4803398176440.45%COSM3186044NA
C. Novel Variants
GeneRefseqIDExonDNAchangeAAchangeFuncChrPosRead depthVAFCOSMICdbSNP
SDHCNM_003001exon2c.25G>Ap.V9Inonsynonmous SNVchr1:16129340868955.15%rs774768866
ALKNM_004304exon18c.3035C>Tp.T1012Mnonsynonmous SNVchr2:29449820133246.1%rs35073634
ERBB4NM_005235exon24c.2935C>Gp.R979Gnonsynonmous SNVchr2:212286761117745.2%rs574197848
BARD1NM_000465exon4c.722C>Gp.S241Cnonsynonmous SNVchr2:215645876239746.06%rs3738885
HIST1H2BJNM_021058exon1c.215A>Gp.E72Gnonsynonmous SNVchr6:27100315166047.89%NA
KDM4CNM_015061exon18c.2447G>Ap.R816Qnonsynonmous SNVchr9:7103707105544.36%rs180710573
ABL1NM_007313exon10c.1601T>Cp.V534Anonsynonmous SNVchr9:13375591755940.97%rs776483252
NUP98NM_016320exon11c.1192A>Gp.S398Gnonsynonmous SNVchr11:377462193746.42%rs144302699
PTPRONM_030667exon17c.2648A>Tp.Y895Fnonsynonmous SNVchr12:15713183155349.45%rs759525747
FANCANM_000135exon42c.4232C>Tp.P1411Lnonsynonmous SNVchr16:89805318123045.61%rs201494304
GTSE1NM_016426exon9c.1688G>Cp.R563Tnonsynonmous SNVchr22:46722515113547.84%rs760482340
PCLONM_033026exon2c.1561C>Gp.P521Anonsynonmous SNVchr7:8278439661814.24%NA

Table 2

Results of next generation gene sequencing after imatinib treatment. The oncogenic mutation (PRKG2/PDGFRA translocation) has disappeared.

A. Annotated variants
B. Known variants
GeneRefseqIDExonDNAchangeAAchangeFuncChrPosRead depthVAFCOSMICdbSNP
MKI67NM_002417exon14c.9670C>Tp.R3224Wnonsynonmous SNVchr10:129899557225441.33%COSM916078rs754802357
ZNF24NM_006965exon3c.427C>Tp.L143Fnonsynonmous SNVchr18:32919934144744.3%COSM5854150rs148053646
GeneRefseqIDExonDNAchangeAAchangeFuncChrPosRead depthVAFCOSMICdbSNP
MKI67NM_002417exon13c.4991_4992delp.T1664fsframeshift insertionchr10:12990511234862.35%COSM916119rs145960091
C. Novel variants
GeneRefseqIDExonDNAchangeAAchangeFuncChrPosRead depthVAFCOSMICdbSNP
SDHCNM_003001exon2c.25G>Ap.V9Inonsynonmous SNVchr1:16129340863352.45%rs774768866
ERBB4NM_005235exon24c.2935C>Gp.R979Gnonsynonmous SNVchr2:212286761162044.88%rs574197848
BARD1NM_000465exon4c.722C>Gp.S241Cnonsynonmous SNVchr2:215645876288946.49%rs3738885
FGFR4NM_002011exon13c.1817G>Ap.R606Qnonsynonmous SNVchr5:17652272024348.56%rs757092386
HIST1H2BJNM_021058exon1c.215A>Gp.E72Gnonsynonmous SNVchr6:27100315215450.0%NA
ABL1NM_007313exon10c.1601T>Cp.V534Anonsynonmous SNVchr9:13375591771842.9%rs776483252
NUP98NM_016320exon11c.1192A>Gp.S398Gnonsynonmous SNVchr11:3774621128345.91%rs144302699
PTPRONM_030667exon17c.2648A>Tp.Y895Fnonsynonmous SNVchr12:15713183152148.06%rs759525747
FANCANM_000135exon42c.4232C>Tp.P1411Lnonsynonmous SNVchr16:89805318174746.48%rs201494304
GTSE1NM_016426exon9c.1688G>Cp.R563Tnonsynonmous SNVchr22:46722515141546.08%rs760482340
RUNX1NM_001754exon9c.1270T>Gp.S424Anonsynonmous SNVchr21:3616460522525.33%NA

Figure 1. Bone marrow aspiration demonstrating a lack of particles and peripheral dilution. Immature cells are occasionally noted (×200).

Figure 2. Trephine bone marrow biopsy showing approximately 60% cellularity, with increased atypical megakaryocytes and fibrosis (Hematoxylin & Eosin staining, ×200).

Translocation of PDGRFA-PRKG2 is uncommon in MPNs. Here, we report a rare case of a patient presenting with a Philadelphia-negative MPN with peripheral basophilia. These results are the first report of PDGRFA-PRKG2 fusion in an MPN-u case. This case shows that the use of imatinib is very effective in specific MPNs with the PDGRFA-PRKG2 translocation. The most intensively studied PDGFRA mutation is FIP1L1-PDGFRA, a karyotypically occult del(4)(q12) described in 2003 as an imatinib-sensitive activation mutation. The FIP1L1-PDGFR fusion gene is an ∼800 kb interstitial deletion within 4q12 that fuses the 5′ portion of FIP1L1 to the 3′ portion of PDGFRA and is a novel molecular mechanism for generating a compositionally activated fusion tyrosine kinase. The breakpoint of FIP1L1 has been observed at various positions, but the PDGFRA breakpoint is specific to exon 12, which encodes part of the protein-protein interaction module with two fully conserved tryptophans containing the JM region. As a result, automatic prohibition activities are suspended, leading to disruption of its autoinhibitory activity [9]. Although FIP1L1-PDGFRA occurs in a small number of patients with phenotypic features of systemic mastocytosis or hypereosinophilic syndrome, the presence of this mutation reliably predicts complete hematological and molecular responses to imatinib therapy [10]. In addition, PDGFRA activation associated with chronic eosinophilic leukemia is described by karyotypically apparent fusion mutations such as KIF5B-PDGFRA t(4:10)(q12;p11) [11], BCR-PDGFRA, t(4;22)(q12;q11) [12], and CDK5RAP2-PDGFRA, ins(9;4) (q33;q12q25) [13].

KIF5B is the third PDGFRA partner gene identified after BCR and FIP1L1, and encodes kinesin family member 5b, a microtubule-based motor protein involved in organ transport. The KIF5B protein is composed of three structural regions: an N-terminal region that hydrolyzes ATP and binds microtubules, a large central helicoil region, and a C-terminal region that interacts with other proteins, blood vessels, and membrane organs. The KIF5B-PDGFR fusion protein contains most of the first two structural domains of KIF5B, including six of the seven coil domains and the entire kinase domain of PDGFRA [11].

CDK5 regulatory subunit-related protein 2 (CDK5RAP2) encodes a protein that is thought to be involved in regulating the formation and stability of microtubules from the centrosome. A new mRNA in-frame fusion between exon 13 of the CDK5RAP2 gene, and truncated PDGFRA exon 12, were identified by rapid amplification of cDNA ends with the polymerase chain reaction. The CDK5RAP2-PDGFRA protein, which is composed of 1,003 amino acids, preserves both the tyrosine kinase domain of PDGFRA and several potential dimerization domains of CDK5RAP2 [13]. In 1994, the Golub and Gililand groups described ETV6-PDGFRB fusion as the first of these fusion genes in patients with chronic myelomonocytic leukemia with eosinophilia and t(5;12) [14]. This gene encodes a protein that belongs to the serine/threonine protein kinase family of proteins. The encoded protein then binds to and inhibits the activation of several receptor tyrosine kinases. Alternate splicing results in multiple transcript variants encoding distinct isoforms whose regulatory N-termini differ in length but whose C-terminal catalytic domains are identical.

The PRKG2 gene encodes a protein that belongs to the serine/threonine protein kinase family of proteins. The encoded protein binds to and inhibits the activation of several receptor tyrosine kinases and plays a role in regulating fluid balance in the intestine. Membrane-bound proteins are regulators of the intestinal secretion, bone growth, and renin secretion. Diseases associated with PRKG2 include chromosome 4Q21 deletion syndrome and cystic fibrosis. Among its related pathways are Sertoli-Sertoli cell junction dynamics and signaling by G-protein coupled receptors [15]. The PRKG2-PDGFRB fusion gene associated with t(4;5)(q21;q33) has been reported previously in only a few patients that presented with systemic mastocytosis, basophilia, thrombocytosis, and massive splenomegaly, with a myeloid neoplasm and PRKG2-PDGFRB rearrangement [16]. Our case, together with those cases in the literature, suggests an association between PDGRFA-PRKG2 and basophilia without mastocytosis. Our patient responded well to imatinib therapy. Further studies are needed to determine if the PDGRFA-PRKG2 fusion is harbored by basophils, which would suggest that cases may represent a distinct clonal disorder. In conclusion, this case highlights the fact that patients with PDGRFA-PRKG2 fusion respond favorably to imatinib. Genetic analysis by NGS in ambiguous blood cancers is essential for identifying appropriate targeted treatment, and further research is warranted.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

  1. Gatter KC, Warnke RA, Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 1991:177-8.
  2. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312.
    Pubmed PMC CrossRef
  3. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
    Pubmed CrossRef
  4. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
    Pubmed CrossRef
  5. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007;109:4635-40.
    Pubmed CrossRef
  6. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002;11:1391-7.
    Pubmed CrossRef
  7. Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007;138:77-81.
    Pubmed CrossRef
  8. Walz C, Schultheis B, Metzgeroth G, et al. Transient response to imatinib in an atypical chronic myeloproliferative disease associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA fusion gene. Blood 2005;106:3281-6.
  9. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005;19:792-8.
    Pubmed CrossRef
  10. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004;103:473-8.
    Pubmed CrossRef
  11. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006;20:827-32.
    Pubmed CrossRef
  12. Yigit N, Wu WW, Subramaniyam S, Mathew S, Geyer JT. BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. Cancer Genet 2015;208:404-7.
    Pubmed CrossRef
  13. Walz C, Curtis C, Schnittger S, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins (9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006;45:950-6.
    Pubmed CrossRef
  14. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
    Pubmed CrossRef
  15. Roy A, Groten J, Marigo V, Tomar T, Hilhorst R. Identification of novel substrates for cGMP dependent protein kinase (PKG) through kinase activity profiling to understand its putative role in inherited retinal degeneration. Int J Mol Sci 2021;22:1180.
    Pubmed PMC CrossRef
  16. Lahortiga I, Akin C, Cools J, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008;93:49-56.
    Pubmed CrossRef


This Article

Current Issue


SCImago Journal & Country Rank

Indexed/Covered by

Today : 295  /
Total : 497,902